Speedel presents data on candidates at Hypertension 2008

Speedel presented data for two of its developmental product candidates, SPP635 and SPP301 (avosentan), at the Hypertension 2008 joint conference of the International Society of Hypertension and the European Society of Hypertension, held in Berlin, Germany.

SPP635 is a renin inhibitor for the treatment of mild-to-moderate hypertension in diabetic patients. It showed a good safety and efficacy profile compared to placebo in a double-blind, placebo-controlled, randomized, parallel-design Phase IIa clinical study, according to the firm.

SPP301 is an endolethin receptor A agonist for diabetic patients, currently in preclinical stages. The firm claims the ASCEND animal study provides a rationale for a Phase II trial with lower doses of the candidate in patients with diabetes, as higher doses were shown to cause extravastation.